Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the "generic rule" valid for small chemical entities. In response, a dedicated regulation was issued in the European Union. It is based on the concept of "biological medicinal products similar to a biological reference product", or "biosimilars". This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature. This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context.
"synopsis" may belong to another edition of this title.
‘Biosimilars’ are copies of biological medicinal products no longer protected by certification. Detailing new EU legal and regulatory frameworks on biosimilars, this book also analyzes their safety, marketing, and funding, and includes a section on US rules.
Jean-Louis Prugnaud is a pharmacist, former head of pharmacy department at Saint-Antoine Hospital, Paris, France. He is Member of the French Commission of drugs’ distribution authorization, President of the Commission of gene and cellular therapy and President of the pharmaceutical working group on biological and biothechnological drugs. Jean-Hugues Trouvin works at AFSSAPS (French health products safety agency) and at the pharmaceutical and biological sciences department at the Paris Descartes University in Paris, France. Preface: Christian K. Schneider is Chairman, CHMP of the Similar Biological (Biosimilar) Medicinal Products Working Party (BMWP), member of the European Medicines Agency( London, United Kingdom) and works at the Paul-Ehrlich-Institut, Federal Agency for Sera and Vaccines (Langen, Germany) and at the Centre for Experimental and Clinical Infection Research (Hannover, Germany).
"About this title" may belong to another edition of this title.
Shipping:
£ 15
From United Kingdom to U.S.A.
Seller: booksXpress, Bayonne, NJ, U.S.A.
Soft Cover. Condition: NEW. Seller Inventory # 9782817805146
Quantity: 10 available
Seller: Lucky's Textbooks, Dallas, TX, U.S.A.
Condition: NEW. Seller Inventory # ABLIING23Mar3012140348836
Quantity: Over 20 available
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: NEW. Seller Inventory # 23055067-n
Quantity: 5 available
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: NEW. PRINT ON DEMAND Book; New; Fast Shipping from the UK. No. book. Seller Inventory # ria9782817805146_lsuk
Quantity: Over 20 available
Seller: GreatBookPricesUK, Castle Donington, DERBY, United Kingdom
Condition: New. Seller Inventory # 23055067-n
Quantity: 5 available
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the 'generic rule' valid for small chemical entities. In response, a dedicated regulation was issued in the European Union. It is based on the concept of 'biological medicinal products similar to a biological reference product', or 'biosimilars'. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature. This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context. 108 pp. Englisch. Seller Inventory # 9782817805146
Quantity: 2 available
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: NEW. 1st edition. 87 pages. 9.00x6.00x0.25 inches. In Stock. Seller Inventory # x-2817805143
Quantity: 2 available
Quantity: Over 20 available
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Biologics have revolutionised the treatment of many severe conditions, delivering exceptional clinical results but also producing exceptionally high prices. As patents expire, copies and price competition are expected throughout the world. However, due to the intrinsic heterogeneity and molecular complexity of biologic medicinal products, their copies cannot simply be authorized under the 'generic rule' valid for small chemical entities. In response, a dedicated regulation was issued in the European Union. It is based on the concept of 'biological medicinal products similar to a biological reference product', or 'biosimilars'. This book analyses the context of biotechnological production and addresses the European legal framework for biosimilar market approval. It highlights post-market authorisation issues, such as Risk Management Plans and substitution of products, and outlines some other issues, such as cost management and international nomenclature. This book is primarily intended for hospital-based physicians and pharmacists. It will also be a valuable resource for all actors from all countries who want to better understand the emergence of these new medicinal products within the European context. Seller Inventory # 9782817805146
Quantity: 1 available
Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Ireland
Condition: NEW. 'Biosimilars' are copies of biological medicinal products no longer protected by certification. Detailing new EU legal and regulatory frameworks on biosimilars, this book also analyzes their safety, marketing, and funding, and includes a section on US rules. Editor(s): Prugnaud, Jean-Louis; Trouvin, Jean-Hugues. Num Pages: 90 pages, 5 black & white tables, biography. BIC Classification: MJCL; MJCM; MJR; MQP; TDCW. Category: (G) General (US: Trade). Dimension: 235 x 155 x 6. Weight in Grams: 180. . 2012. Paperback. . . . . Seller Inventory # V9782817805146
Quantity: 15 available